ByLisaU

Freelance pharma and biotech editor/writer, interested in health inequality, pharma AI and drug discovery and development. DM or email me at [email protected]

[Amy Brown @ByAmyBrown]

Can Enhertu push on the HER2-low door once again? My quick take for @apexonco https://t.co/PnRYjz5Me1 $AZN $DSNKY

[Joanne Fagg @ByJoFagg]

Good timing for my Pdufa story given the $BIIB $RETA news, Zuranolone's decision is due 5 Aug.
Check out the full August table here👉https://t.co/JduZYUKvr2 #FDA $SAGE $ALPMY $APLS $REGN $PFE $NVS #ASRS2023

[ByLisaU @ByLisaU]

Biogen's Chris Viehbacher $BIIB makes big $7.3bn M&A move for $RETA, but is it too pricey? Mine and @EdwinElmhirst's take via @evaluatevantage https://t.co/DCVqsRxVab

[Elizabeth Cairns @ByLizC]

The $LLY vs $NVO grudge match continues, with the US group winning another couple of rounds in obesity
https://t.co/TXWqkxyDZg

[ByLisaU @ByLisaU]

Investors unimpressed at Viehbacher's attempts to clean house as $BIIB shares fall. My quick take via @Evaluatevantage https://t.co/7jaemXKFFi

[Jacob Plieth @JacobPlieth]

And now the $FGEN CEO is out. https://t.co/wB0QjKJtSa

[Joanne Fagg @ByJoFagg]

The urticaria pipeline is pretty busy, but can anyone beat Xolair? Here's a look at the late-stage projects due to report clinical data in the next six to 12 months
👉https://t.co/CEM2U9bIib
$NVS $RHHBY $SNY $REGN $AMGN $AZN $ALLK $CLDX

[Jacob Plieth @JacobPlieth]

Another Q2 $NVS discontinuation: MBL949, now revealed to have been a GDF-15 (inhibitor?) for obesity. Remember company had highlighted this as an asset for investors to watch in Q1, just 3 mths ago

[Madeleine Armstrong @ByMadeleineA]

$ABOS's new amyloid approach impresses at #AAIC2023, but how differentiated will it turn out to be? I interviewed the company for @evaluatevantage https://t.co/q7EiC249vq

[Madeleine Armstrong @ByMadeleineA]

$LLY downplays tau testing needs as full donanemab phase 3 data presented at #AAIC2023. My take via @evaluatevantage https://t.co/Xdlu9ca18b

[Elizabeth Cairns @ByLizC]

$BBIO turns a failure into a success; might partners come knocking?
https://t.co/k3VNyhRSqu

[pharma father @pharmafather123]

The year is 2040. Every incretin known to man has been combined into a weight loss drug. 100% weight loss. It’s a euthanasia drug. Degrades your bones and your organs. Life is good.

[Jacob Plieth @JacobPlieth]

$QURE hails AMT-130 efficacy, but that's questionable, and the Huntington’s gene therapy has other, more fundamental problems. Via @evaluatevantage -> https://t.co/SU2XuRdKDA

[Joanne Fagg @ByJoFagg]

ICYMI all the key FDA Pdufa and adcom dates this month: https://t.co/lOQvdvV9j6
This week:
📣Beyfortus (nirsevimab) RSV adcom tomorrow $SNY $AZN
📣Leqembi confirmatory study adcom 9 June $EASLY $ESALF $BIIB

[Jacob Plieth @JacobPlieth]

And now Dizal's data with sunvozertinib (the EGFR star of #Asco21) in pivotal Wukong6 trial in 2L exon20 ins. Note responses in post-Rybrevant patients, via Mengzhao Wang: $AZN $JNJ $TAK #Asco23

[Amy Brown @ByAmyBrown]

The search is on for early signals in front-line NSCLC for datopotamab, the Trop2 ADC that is already in three pivotal trials. My take on the #ASCO23 data: https://t.co/TykRq44a0Z $AZN $DSNKY

[Amy Brown @ByAmyBrown]

#ASCO23 Bicara's impressive data in head and neck cancer (48% ORR, 65% in HPV negative disease) potential beats Keytruda, and has the private group making pivotal plans. I spoke to CEO Claire Mazumdar: https://t.co/jZAtrCGslI $MRK

[Jacob Plieth @JacobPlieth]

@PinkSheetSutter @FDApanels As expected then: FDA expands $AZN $MRK Lynparza use to prostate cancer - but only in Brca +ves https://t.co/E8grnN0bRP

[Elizabeth Cairns @ByLizC]

Another of $PFE's haemophilia candidates succeeds in phase 3 - but can it get past the regulators? https://t.co/DSlSQCVi2C

[Jacob Plieth @JacobPlieth]

Tigit FTW! First take on some #Asco23 abstracts, plus what's in the late-breakers? Via @evaluatevantage -> https://t.co/bUKEh9uHR5 $ITOS $RCUS $CGEN $NVS $IMGN $AZN